Emmaus Life Sciences (EMMA) Stock Price, News & Analysis

Company Overview

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

Key Stats

• Today's Range: $0.0158 to $0.0158
• 50-Day Range: $0.0120 to $0.0199
• 52-Week Range: $0.00 to $0.10
• Volume: N/A
• Average Volume: 42,207 shs
• Market Capitalization: $1.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Emmaus Life Sciences Stock Analysis - MarketRank™

Emmaus Life Sciences scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Emmaus Life Sciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Emmaus Life Sciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Emmaus Life Sciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Emmaus Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Emmaus Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Emmaus Life Sciences has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Emmaus Life Sciences does not currently pay a dividend.

Dividend Growth

Emmaus Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Emmaus Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Emmaus Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Emmaus Life Sciences has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Emmaus Life Sciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Emmaus Life Sciences this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Emmaus Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

35.00% of the stock of Emmaus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.42% of the stock of Emmaus Life Sciences is held by institutions.

EMMA Stock Analysis - Frequently Asked Questions

How have EMMA shares performed this year?

Emmaus Life Sciences' stock was trading at $0.0085 on January 1st, 2025. Since then, EMMA stock has increased by 86.1% and is now trading at $0.0158.
View the best growth stocks for 2025 here.

How were Emmaus Life Sciences' earnings last quarter?

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) released its quarterly earnings results on Thursday, May, 15th. The company reported ($0.04) earnings per share (EPS) for the quarter.

How do I buy shares of Emmaus Life Sciences?

Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Emmaus Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Emmaus Life Sciences investors own include Humanigen (HGEN), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Acasti Pharma (ACST), Actinium Pharmaceuticals (ATNM) and Entasis Therapeutics (ETTX).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 6/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:EMMA
• CIK: 822370
• Web: www.emmausmedical.com
• Phone: (310) 214-0065
• Fax: 866-294-2611
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.73 million
• Net Margins: -17.11%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -12.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.14
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: $29.60 million
• Price / Sales: 0.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 63,866,000
• Free Float: 41,513,000
• Market Cap: $1.01 million
• Optionable: Not Optionable
• Beta: 8.37